Incretin-based Therapy in Preclinical Type 1 Diabetes in Adults

Phase 2 Unknown 42 enrolled University of Oulu Oulu University Hospital · collab Tampere University Hospital · collab Turku University Hospital · collab

RandomizedParallel-groupQuadruple-blindPrevention

Summary

The main objectives of the trial are to study whether daily treatment with liraglutide improves insulin secretion and glucose metabolism, and whether liraglutide treatment is tolerable and safe in subjects with preclinical type 1 diabetes aged 18-30 years.

Timeline

Start: 2015-12
Primary completion: 2024-06
Completion: 2024-06

Publications

Kero J, Koskenniemi JJ, Karsikas S, Pokka T, Lou O, Toppari J, Veijola R. INnoVative trial design for testing the Efficacy, Safety and Tolerability of 6-month treatment with incretin-based therapy to prevent type 1 DIAbetes in autoantibody positive participants: A protocol for three parallel double-blind, randomised controlled trials (INVESTDIA). Diabet Med. 2022 Oct;39(10):e14913. doi: 10.1111/dme.14913. Epub 2022 Jul 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Liraglutide	Peptide	1.8 mg	Subcutaneous

Incretin-based Therapy in Preclinical Type 1 Diabetes in Adults

Summary

Timeline

Publications

Drugs

Indications